NEW YORK (TheStreet) -- CHANGE IN RATINGS

Boeing

(BA) - Get Report

upgraded at Jesup & Lamont from Hold to Buy. $63 price target. Stock is trading at an attractive risk/reward ratio.

Boeing

(BA) - Get Report

upgraded at Barclays to Overweight from Equal Weight. Price target jumped to $65 from $57. 2009 and 2010 EPS estimates lowered to $1.20 and $4.40, respectively.

Beckman Coulter

( BEC) upgraded at JP Morgan. Rating raised to Overweight from Neutral. Maintains $75 price target and 2009 EPS estimates of $3.82.

Boston Scientific

( BUCY) downgraded at Baird from Outperform to Neutral. $10 price target. Company is reliant on slow-growth markets.

Bucyrus

( BUCY) target, estimate raised at Barclays. BUCY price target surged to $73 from $64. 2010 EPS estimate increased to $3.55 from $2.90. Maintain Overweight rating.

Bucyrus

( BUCY) rated new Outperform at Morgan Stanley. $71 price target. Terex purchase was a positive and should materially add to earnings.

Chesapeake Energy

(CHK) - Get Report

downgraded at Goldman from Buy to Neutral. Valuation call, despite the company's attractive resource upside.

Con-way

(CNW)

upgraded at BofA/Merrill to Buy from Neutral. Price target set at $45. YRC's market share losses makes valuation increasingly attractive for CNW.

Calpine

(CPN)

upgraded at Jefferies from Underperform to Hold. $11.50 price target. Company has reduced exposure to gas and trades at an attractive valuation.

Dynegy

(DYN)

upgraded at Jefferies from Underperform to Hold. Valuation call, based on a $1.80 price target.

Brinker

(EAT) - Get Report

downgraded at UBS from Buy to Neutral. $16 price target. Estimates also lowered, as sales trends appear to have deteriorated.

Emdeon

( EM) upgraded at Brean Murray from Sell to Hold. Company is likely to exceed conservative earnings expectations.

Edwards Lifesciences

(EW) - Get Report

upgraded at Baird from Neutral to Outperform. $103 price target. Sapien launch should be successful.

Expedia

(EXPE) - Get Report

downgraded at Credit Suisse to Neutral from Outperform as risk/reward appears balanced. Price target cut by a dollar to $28. 2009 and 2010 EPS estimates set at $1.37 and $1.44, respectively.

Hansen Medical

(HNSN)

downgraded at JP Morgan. Rating lowered to Neutral from Overweight. Eliminates price target. Lowers 2009 EPS estimates to -$1.45 from -$1.42.

Intel

(INTC) - Get Report

upgraded at Baird from Neutral to Outperform. $26 price target. Expect further growth in PC sales trends.

Las Vegas Sands

(LVS) - Get Report

upgraded at UBS from Neutral to Buy. $20 price target. Expect the company to take market share in a growing Macau market.

Mercadolibre

( ME) downgraded at JP Morgan. Rating lowered to Neutral from Overweight. Maintains $51 price target and 2009 EPS estimates of $0.74.

Morgan Stanley

(MS) - Get Report

upgraded at Credit Suisse to Outperform from Neutral. Anticipating weak 4Q but 2010 should see margins and book value growth, Credit Suisse said. Price target raised to $38 from $32. 2009 EPS sunk to -$1.08, 2010 raised to $3.20.

Morgan Stanley

(MS) - Get Report

upgraded at UBS from Neutral to Buy. $37 price target. Investment Banking pipeline is building and management is turning around some areas that have struggled.

NII Holdings

(NIHD) - Get Report

rated new Buy at Citigroup. $50 price target. Stock appears under-owned and the company is operating in a sweet spot.

Plains Exploration

(PXP)

rated new Neutral at Goldman. $33 price target. Company needs to execute better to attract investors.

Silicon Laboratories

(SLAB) - Get Report

downgraded at Kaufman from Buy to Hold. $50 price target. Most recent checks suggest work down of handset inventories in Korea.

UnitedHealth

(UNH) - Get Report

upgraded at Citigroup from Hold to Buy. Company should benefit from sector rotation. $39 price target.

Ultra Petroleum

(UPL)

upgraded at Goldman from Neutral to Buy. Stock also added to the Conviction List, as growth and returns should be strong outside of the price of natural gas.

UPS

(UPS) - Get Report

upgraded at Baird from Neutral to Outperform. $70 price target. See multiple areas for operating leverage, as the environment improves.

Wellcare

(WCG) - Get Report

downgraded at Oppenheimer from Outperform to Perform. $36 price target. Valuation call, as the company likely has limited upside earnings potential.

Wynn Resorts

(WYNN) - Get Report

upgraded at UBS from Neutral to Buy. $76 price target. Valuation call, as the Macau gaming outlook remains steady.

STOCK COMMENTS / EPS CHANGES

Atmel

(ATML)

added to Focus List at Kaufman. $6 price target. Channel checks show strong demand across key segments. Buy rating.

Bristol-Myers

(BMY) - Get Report

target upped at Goldman. Shares of BMY now seen reaching $26. MJN split will boost the company's earnings. Neutral rating.

Citigroup

(C) - Get Report

estimate lower at Credit Suisse. C 2009 EPS to -$0.60 from -$0.05, 2010 set at $0.12. Maintain Neutral rating and $4.50 price target.

CME Group

(CME) - Get Report

estimates cut at Barclays. Barclays lowered CME 2009 and 2010 EPS estimates to $13.25 and $15.68, respectively. Maintain Equal Weight rating and $315 price target.

Express Scripts

(ESRX)

target boosted at Citigroup Shares of ESRX now seen reaching $112, according to Citigroup. Industry has favorable tailwinds. Buy rating.

Google

(GOOG) - Get Report

estimates, target raised at FBR. Shares of GOOG now seen reaching $810. Estimates also boosted, to reflect channel checks and the latest traffic data. Outperform rating.

Goldman Sachs

(GS) - Get Report

estimate cut at Credit Suisse. GS 2009 EPS estimate to $18.08 from $19.30, 2010 set at $17.75. Maintain Outperform rating and $225 price target.

Intercontinental Exchange

(ICE) - Get Report

target, estimates cut at Barclays. ICE price target lowered by $3 to $116. 2009 and 2010 EPS estimates reduced to $4.45 and $5.26, respectively. Maintain Overweight rating.

Joy Global

( JOYG) target, estimates raised at Barclays to $67 from $64 on faster recovery. 2010 EPS estimate improved to $3.05, 2011 introduced at $3.95. Reiterate Overweight rating.

Mariner Energy

(ME)

price target lowered at Credit Suisse by a dollar to $15. 2009 and 2010 EPS estimates set at $0.70 and $0.03, respectively. Outperform rating.

Medco Health

(MHS)

target increased at Citigroup. MHS target was boosted to $77. Prescription trends remain favorable. Buy rating.

Merck

(MRK) - Get Report

numbers boosted at Citigroup. MRK estimates were increased through 2013. Company should see significant synergies from the SGP deal. Buy rating and new $45 price target.

NYSE Euronext

(NYX)

estimates lower at Barclays.Barclays reduced NYX 2009 and 2010 EPS estimates to $1.94 and $2.28, respectively. Reiterate Overweight rating and $35 price target.

Sprint Nextel

(S) - Get Report

estimates lowered at Goldman through 2011. Company to see higher losses following the recent Clearwire financing. Neutral rating.

Skyworks

(SWKS) - Get Report

estimates, target boosted at Oppenheimer. Shares now seen reaching $17. Estimates also raised, as channel checks show the company has strong order momentum. Outperform rating.

AT&T

(T) - Get Report

estimates boosted at Goldman through 2011. Centennial acquisition should add to earnings. Buy rating.

Veeco Instruments

(VECO) - Get Report

price target raised at BofA/Merrill to $40 from $33 as LED cycle remains robust. Reiterate Buy rating.

This article was written by a staff member of TheStreet.com.